Apalutamide
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Apalutamide
Apalutamide: Known uses and market status in Australia
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Apalutamide, so there is currently no new predicted indication. The drug’s recorded uses are listed below: one is supported by a licence in another country, and three are relations recorded in the knowledge graph.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 4 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| prostatic neoplasms | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| familial prostate carcinoma |
| prostate cancer |
| prostate carcinoma |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 12992T | Erlyand | Tablet 60 mg | Valid |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted hormonal therapy (androgen receptor inhibitor), not a conventional cytotoxic |
| Myelosuppression Risk | Please refer to the Product Information (PI) warnings and precautions |
| Emetogenicity Classification | Please refer to the Product Information (PI) warnings and precautions |
| Monitoring Items | Please refer to the PI. Thyroid function, fracture and fall risk, and skin reactions are relevant to this drug class. |
| Handling Protection | Please refer to the PI and local handling guidance |
Safety Considerations
- Drug Interactions: 100 interactions were identified in the interaction database. Those listed in the data compiled for this report include the following.
- Major: bupropion, cisapride, dolasetron, eliglustat
- Moderate: famotidine, rabeprazole, esomeprazole, hydrocortisone, clarithromycin, glimepiride, glipizide, chlorpropamide, dapagliflozin, empagliflozin, loperamide, bisacodyl, alosetron, alvimopan, fidaxomicin, castor oil
- Known toxicity profile (from the prediction rationale): rash, fatigue, fracture and fall risk, and hypothyroidism.
Label warnings and contraindications were not available. Please refer to the TGA-approved Product Information (PI) for full safety information.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.